Full Text:   <876>

Summary:  <349>

CLC number: R459.5

On-line Access: 2016-05-04

Received: 2015-09-26

Revision Accepted: 2015-12-30

Crosschecked: 2016-04-15

Cited: 0

Clicked: 2086

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Xi-shao Xie

http://orcid.org/0000-0001-9049-1701

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2016 Vol.17 No.5 P.375-381

http://doi.org/10.1631/jzus.B1500235


Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study


Author(s):  Xi-shao Xie, Zhou-tao Xie, Shi-long Xiang, Xing-qun Yan, Xiao-hui Zhang, Zhang-fei Shou, Jiang-hua Chen

Affiliation(s):  Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

Corresponding email(s):   zfshou@zju.edu.cn

Key Words:  Peritoneal dialysis (PD), Autosomal dominant polycystic kidney disease (ADPKD), Outcome, Comorbidity


Xi-shao Xie, Zhou-tao Xie, Shi-long Xiang, Xing-qun Yan, Xiao-hui Zhang, Zhang-fei Shou, Jiang-hua Chen. Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study[J]. Journal of Zhejiang University Science B, 2016, 17(5): 375-381.

@article{title="Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study",
author="Xi-shao Xie, Zhou-tao Xie, Shi-long Xiang, Xing-qun Yan, Xiao-hui Zhang, Zhang-fei Shou, Jiang-hua Chen",
journal="Journal of Zhejiang University Science B",
volume="17",
number="5",
pages="375-381",
year="2016",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1500235"
}

%0 Journal Article
%T Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study
%A Xi-shao Xie
%A Zhou-tao Xie
%A Shi-long Xiang
%A Xing-qun Yan
%A Xiao-hui Zhang
%A Zhang-fei Shou
%A Jiang-hua Chen
%J Journal of Zhejiang University SCIENCE B
%V 17
%N 5
%P 375-381
%@ 1673-1581
%D 2016
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1500235

TY - JOUR
T1 - Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study
A1 - Xi-shao Xie
A1 - Zhou-tao Xie
A1 - Shi-long Xiang
A1 - Xing-qun Yan
A1 - Xiao-hui Zhang
A1 - Zhang-fei Shou
A1 - Jiang-hua Chen
J0 - Journal of Zhejiang University Science B
VL - 17
IS - 5
SP - 375
EP - 381
%@ 1673-1581
Y1 - 2016
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1500235


Abstract: 
To describe the long-term clinical outcomes of patients with autosomal dominant polycystic kidney disease (ADPKD) who are on peritoneal dialysis (PD) therapy. We performed a retrospective matched-cohort analysis comparing the clinical outcomes of 30 ADPKD patients with those of 30 non-diabetic patients who had bilateral small kidneys between July 1 2007 and July 31 2014. The patient groups were matched by age, gender, and time of PD initiation. There were no significant differences in the demographic or biochemical parameters, comorbid conditions, residual glomerular filtration rate, or Charlson comorbidity score at the beginning of PD. The median renal volume was 1315 ml for the ADPKD group and 213 ml for the control group. Patients with ADPKD had similar 3-year patient survival (90.6% versus 86.3%, P=0.807) and technique survival (89.2% versus 74.3%, P=0.506) compared with non-ADPKD patients. Also, there was no significant difference in the peritonitis-free survival between the ADPKD and control groups (P=0.22), and rates of peritonitis were similar (0.19 versus 0.21 episodes per patient-year, P=0.26). No differences were observed in the incidence of PD-related complications, such as hernia and dialysate leak. ADPKD is not a contraindication for PD, and a subgroup of ADPKD patients with relatively small kidney volume can be treated using PD.

多囊肾患者行腹膜透析的预后分析

目的:探讨多囊肾致终末期肾病患者行腹膜透析治疗的预后情况。
创新点:分析国内最大一组单中心样本关于多囊肾患者行腹膜透析治疗的预后研究,进一步证实多囊肾并非腹膜透析的禁忌症。
方法:回顾性分析2007年7月1日至2014年7月31日于我院置管并开始维持性腹膜透析的30例多囊肾致终末期肾病患者,选择30例年龄及性别与多囊肾组匹配的非多囊肾患者作为对照组。记录患者一般资料、透析初始资料、并发症、生存时间、退出透析或死亡等治疗结局。采用Kaplan-Meier法和log-rank检验进行生存分析。
结论:多囊肾组3年病人生存率和技术生存率分别为90.6%和89.2%,对照组为86.3%和74.3%,差异无统计学意义(图1和2)。两组患者的腹膜炎发生率分别为0.19次/病人年和0.21次/病人年(表3)。两组患者腹透液渗漏、疝气、心脑血管事件发生率之间的差异均无统计学意义(表4)。综上所述,通过合理的病人筛选和评估,多囊肾不是腹膜透析的禁忌症。

关键词:腹膜透析;多囊肾;预后;并发症

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Bae, K.T., Grantham, J.J., 2010. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol., 6(2):96-106.

[2]Beddhu, S., Bruns, F.J., Saul, M., et al., 2000. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am. J. Med., 108(8):609-613.

[3]Chapman, A.B., Devuyst, O., Eckardt, K.U., et al., 2015. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int., 88(1):17-27.

[4]del Peso, G., Bajo, M.A., Costero, O., et al., 2003. Risk factors for abdominal wall complications in peritoneal dialysis patients. Perit. Dial. Int., 23(3):249-254.

[5]Fick-Brosnahan, G.M., Belz, M.M., McFann, K.K., et al., 2002. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis., 39(6):1127-1134.

[6]Fletcher, S., Turney, J.H., Brownjohn, A.M., 1994. Increased incidence of hydrothorax complicating peritoneal dialysis in patients with adult polycystic kidney disease. Nephrol. Dial. Transplant., 9(7):832-833.

[7]Grantham, J.J., Torres, V.E., Chapman, A.B., et al., 2006. Volume progression in polycystic kidney disease. N. Engl. J. Med., 354(20):2122-2130.

[8]Hadimeri, H., Johansson, A.C., Haraldsson, B., et al., 1998. CAPD in patients with autosomal dominant polycystic kidney disease. Perit. Dial. Int., 18(4):429-432.

[9]Janeiro, D., Portoles, J., Maria Tato, A., et al., 2015. Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study. Perit. Dial. Int., 35(5):530-536.

[10]Kumar, S., Fan, S.L., Raftery, M.J., et al., 2008. Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int., 74(7):946-951.

[11]Li, L., Szeto, C.C., Kwan, B.C., et al., 2011. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis., 57(6):903-907.

[12]Li, P.K., Szeto, C.C., Piraino, B., et al., 2010. Peritoneal dialysis-related infections recommendations: 2010 update. Perit. Dial. Int., 30(4):393-423.

[13]Liu, Z.H., 2013. Nephrology in China. Nat. Rev. Nephrol., 9(9):523-528.

[14]Lobbedez, T., Touam, M., Evans, D., et al., 2011. Peritoneal dialysis in polycystic kidney disease patients. Report from the French peritoneal dialysis registry (RDPLF). Nephrol. Dial. Transplant., 26(7):2332-2339.

[15]Pandya, B.K., Friede, T., Williams, J.D., 2004. A comparison of peritonitis in polycystic and non-polycystic patients on peritoneal dialysis. Perit. Dial. Int., 24(1):79-81.

[16]Spithoven, E.M., Kramer, A., Meijer, E., et al., 2014. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol. Dial. Transplant., 29(Suppl. 4):iv15-iv25.

[17]Twardowski, Z.J., Nolph, K.D., Khanna, R., et al., 1987. Peritoneal equilibration test. Perit. Dial. Int., 7(3):138-147.

[18]Yu, X., Yang, X., 2015. Peritoneal dialysis in China: meeting the challenge of chronic kidney failure. Am. J. Kidney Dis., 65(1):147-151.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE